Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

News

Press Releases

  • Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19
    December 2, 2021
  • Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
    September 21, 2021
  • Pulmotect Appoints William J. Noss III as Chief Financial Officer
    June 29, 2021
  • Pulmotect Awarded Up To $6M From Department of Defense to Complete Two COVID-19 Trials
    January 27, 2021
  • Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19
    May 5, 2020
  • Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection
    January 27, 2020
  • Dr. Colin Broom joins Pulmotect, Inc. as CEO
    October 17, 2019
  • AstraZeneca VP Kumar Srinivasan Joins Pulmotect, Inc. Board of Directors
    October 17, 2019
  • Pulmotect Announces Initial Close on $12 Million Series B
    May 9, 2018
  • Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
    June 15, 2017

More Press Releases

News Coverage

  • Coronavirus protection drug approved by FDA for testing in Houston
    KTRK ABC 13 - July 10, 2020
  • Houston biotech company gets green light from FDA to test coronavirus-fighting drug
    InnovationMap - May 2020
  • Houston company testing drug to protect against COVID 19
    KTRK-TV Houston - ABC 13 - May 2020
  • Houston company working on possible COVID-19 treatment
    Houston Fox 26 News - March 2020
  • Houston biotech co.’s coronavirus treatment candidate to undergo clinical trials
    Houston Business Journal - March 2020
  • Houston researchers test lung inhalant that could protect healthcare workers from COVID-19
    Houston Chronicle - March 2020
  • Houston biopharmaceutical company brings on new CEO to grow company
    InnovationMap - Oct 2019

More News Coverage

Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2023
Pulmotect, Inc.